Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TRVN
CUSIPN/A
Phone610-354-8840
Debt
Debt-to-Equity Ratio0.28
Current Ratio3.40
Quick Ratio3.40
Price-To-Earnings
Trailing P/E Ratio-1.30
Forward P/E Ratio-2.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.75 million
Price / Sales31.85
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book2.80
Profitability
EPS (Most Recent Fiscal Year)($1.21)
Net Income$-71,860,000.00
Net MarginsN/A
Return on Equity-125.40%
Return on Assets-65.85%
Miscellaneous
Employees51
Outstanding Shares76,080,000
Market Cap$124.01 million
Trevena (NASDAQ:TRVN) Frequently Asked Questions
What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How were Trevena's earnings last quarter?
Trevena Inc (NASDAQ:TRVN) announced its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.00. The biopharmaceutical company earned $2.50 million during the quarter, compared to the consensus estimate of $5.50 million. View Trevena's Earnings History.
When is Trevena's next earnings date?
What price target have analysts set for TRVN?
5 brokerages have issued twelve-month price targets for Trevena's stock. Their forecasts range from $2.50 to $10.00. On average, they anticipate Trevena's share price to reach $6.30 in the next twelve months. This suggests a possible upside of 301.3% from the stock's current price. View Analyst Price Targets for Trevena.
What is the consensus analysts' recommendation for Trevena?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevena.
Who are some of Trevena's key competitors?
Some companies that are related to Trevena include Unum Therapeutics (UMRX), Rigel Pharmaceuticals (RIGL), Depomed (DEPO), Akebia Therapeutics (AKBA), Forty Seven (FTSV), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Stemline Therapeutics (STML), Aduro BioTech (ADRO), Synergy Pharmaceuticals (SGYP), Magenta Therapeutics (MGTA), Merus (MRUS), ZEALAND PHARMA/S (ZEAL), ZIOPHARM Oncology (ZIOP) and Dermira (DERM).
Who are Trevena's key executives?
Trevena's management team includes the folowing people:
- Dr. Maxine Gowen, CEO, Pres & Exec. Director (Age 60)
- Ms. Carrie L. Bourdow, Exec. VP & COO (Age 55)
- Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
- Dr. Jonathan Violin Ph.D., Sr. VP of Scientific Affairs & Investor Relations Officer (Age 43)
- Mr. John M. Limongelli, Chief Admin. Officer, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
Has Trevena been receiving favorable news coverage?
News headlines about TRVN stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trevena earned a media and rumor sentiment score of 0.22 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.87 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Trevena.
Who are Trevena's major shareholders?
Trevena's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (6.95%), Northpointe Capital LLC (1.97%), Millennium Management LLC (1.32%), BlackRock Inc. (0.98%), Renaissance Technologies LLC (0.69%) and GSA Capital Partners LLP (0.46%). Company insiders that own Trevena stock include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Institutional Ownership Trends for Trevena.
Which major investors are selling Trevena stock?
Which major investors are buying Trevena stock?
TRVN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Renaissance Technologies LLC, Paloma Partners Management Co, GSA Capital Partners LLP and LMR Partners LLP. Company insiders that have bought Trevena stock in the last two years include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Insider Buying and Selling for Trevena.
How do I buy shares of Trevena?
Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trevena's stock price today?
One share of TRVN stock can currently be purchased for approximately $1.57.
How big of a company is Trevena?
Trevena has a market capitalization of $124.01 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-71,860,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Trevena employs 51 workers across the globe.
How can I contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard Suite 200, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]
MarketBeat Community Rating for Trevena (NASDAQ TRVN)
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
